AXDX vs. OMIC, OPXS, AATC, CLIR, MSAI, DAIO, BNGO, ASTC, PRPO, and STAI
Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include Singular Genomics Systems (OMIC), Optex Systems (OPXS), Autoscope Technologies (AATC), ClearSign Technologies (CLIR), MultiSensor AI (MSAI), Data I/O (DAIO), Bionano Genomics (BNGO), Astrotech (ASTC), Precipio (PRPO), and Scantech AI Systems (STAI). These companies are all part of the "measuring and control equipment" industry.
Accelerate Diagnostics vs.
Accelerate Diagnostics (NASDAQ:AXDX) and Singular Genomics Systems (NASDAQ:OMIC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
17.1% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 65.8% of Singular Genomics Systems shares are held by institutional investors. 43.6% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 22.2% of Singular Genomics Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Accelerate Diagnostics received 342 more outperform votes than Singular Genomics Systems when rated by MarketBeat users. Likewise, 58.68% of users gave Accelerate Diagnostics an outperform vote while only 44.83% of users gave Singular Genomics Systems an outperform vote.
Accelerate Diagnostics has higher revenue and earnings than Singular Genomics Systems. Singular Genomics Systems is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.
Accelerate Diagnostics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Singular Genomics Systems has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.
Accelerate Diagnostics has a net margin of -471.83% compared to Singular Genomics Systems' net margin of -3,237.89%. Accelerate Diagnostics' return on equity of 0.00% beat Singular Genomics Systems' return on equity.
In the previous week, Accelerate Diagnostics had 5 more articles in the media than Singular Genomics Systems. MarketBeat recorded 5 mentions for Accelerate Diagnostics and 0 mentions for Singular Genomics Systems. Accelerate Diagnostics' average media sentiment score of 0.98 beat Singular Genomics Systems' score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the media.
Singular Genomics Systems has a consensus price target of $6.50, indicating a potential downside of 67.52%. Given Singular Genomics Systems' higher probable upside, analysts plainly believe Singular Genomics Systems is more favorable than Accelerate Diagnostics.
Summary
Accelerate Diagnostics beats Singular Genomics Systems on 13 of the 18 factors compared between the two stocks.
Get Accelerate Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Accelerate Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:AXDX) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy AXDX Stock Free AXDX Stock Alerts